Biopharma firm Zetagen raises $9.79m in Series B financing round
Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatments for metastatic cancers to bone and soft tissue organs.
Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatments for metastatic cancers to bone and soft tissue organs.
What's Your Reaction?
